Scholar Rock Announces the Addition of Richard Brudnick to Its Board of Directors
April 10 2023 - 3:05PM
Business Wire
Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage
biopharmaceutical company focused on the treatment of serious
diseases in which protein growth factors play a fundamental role,
today announced that Richard Brudnick, has been appointed to
Scholar Rock’s Board of Directors as an independent director. Mr.
Brudnick is an accomplished biotechnology executive with over three
decades of industry experience specializing in the corporate
development of companies spanning across multiple specialties,
stages and therapeutic areas.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230410005287/en/
(Photo: Business Wire)
“We are pleased to welcome Richard to Scholar Rock’s Board of
Directors. Richard brings extensive corporate development
experience and leadership acumen, having held several executive
positions and currently serving as Chief Business Officer of Prime
Medicine, which will be instrumental as Scholar Rock advances
towards becoming a fully integrated biopharmaceutical company,”
said David Hallal, Chairman of the Board of Scholar Rock. “As
Scholar Rock’s deep pipeline continues to advance, the board and
executive leadership team will benefit from Richard’s decades of
broad experience in corporate development and strategy.”
“Scholar Rock has an impressive pipeline with the potential to
meaningfully improve the lives of patients suffering from a wide
range of serious diseases, including neuromuscular disorders and
cancer,” said Mr. Brudnick. “I am excited to join the company’s
Board of Directors, and I look forward to working with the other
board members and the leadership team at this pivotal stage.”
Mr. Brudnick joined Prime Medicine as Chief Business Officer in
July 2022 and is responsible for corporate development and
strategy. Prior to Prime, he served as Chief Business Officer and
Head of Strategy of Codiak BioSciences, a leader in the field of
exosome therapeutics. Before joining Codiak, Mr. Brudnick served as
Executive Vice President of Business Development and Alliance
Management at Bioverativ, where he led business development efforts
to build a significant pipeline in rare blood disorders. Earlier,
Mr. Brudnick spent nearly 15 years at Biogen where he initiated,
led and completed transactions that led to several marketed
products including Leqembi, Tecfidera, Spinraza and its biosimilars
joint venture with Samsung.
Mr. Brudnick holds an M.S. and B.S. in Management Science from
Massachusetts Institute of Technology Sloan School of Management.
He also serves as a director of InflaRx and Tamarix Pharma.
About Scholar Rock
Scholar Rock is a clinical-stage biopharmaceutical company
focused on the discovery and development of innovative medicines
for the treatment of serious diseases in which signaling by protein
growth factors plays a fundamental role. Scholar Rock is creating a
pipeline of novel product candidates with the potential to
transform the lives of patients suffering from a wide range of
serious diseases, including neuromuscular disorders, cancer, and
fibrosis. Scholar Rock’s approach to targeting the molecular
mechanisms of growth factor activation enabled it to develop a
proprietary platform for the discovery and development of
monoclonal antibodies that locally and selectively target these
signaling proteins at the cellular level. By developing product
candidates that act in the disease microenvironment, the Company
intends to avoid the historical challenges associated with
inhibiting growth factors for therapeutic effect. Scholar Rock
believes its focus on biologically validated growth factors may
facilitate a more efficient development path. For more information,
please visit www.ScholarRock.com or follow Scholar Rock on Twitter
(@ScholarRock) and LinkedIn
(https://www.linkedin.com/company/scholar-rock/).
Availability of Other Information About Scholar Rock
Investors and others should note that we communicate with our
investors and the public using our company website
www.scholarrock.com, including, but not limited to, company
disclosures, investor presentations and FAQs, Securities and
Exchange Commission filings, press releases, public conference call
transcripts and webcast transcripts, as well as on Twitter and
LinkedIn. The information that we post on our website or on Twitter
or LinkedIn could be deemed to be material information. As a
result, we encourage investors, the media and others interested to
review the information that we post there on a regular basis. The
contents of our website or social media shall not be deemed
incorporated by reference in any filing under the Securities Act of
1933, as amended.
Scholar Rock® is a registered trademark of Scholar Rock,
Inc.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements regarding Scholar
Rock’s future expectations, plans and prospects, including without
limitation, Scholar Rock’s expectations regarding its growth,
strategy, progress and development timing, the ability of any
individual to affect the growth, strategy, and progress of Scholar
Rock, and the potential of its product candidates and proprietary
platform. The use of words such as “may,” “might,” “could,” “will,”
“should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,”
“project,” “intend,” “future,” “potential,” or “continue,” and
other similar expressions are intended to identify such
forward-looking statements. All such forward-looking statements are
based on management's current expectations of future events and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks
and uncertainties include, without limitation, Scholar Rock’s
ability to provide the financial support, resources and expertise
necessary to identify and develop product candidates on the
expected timeline, the data generated from Scholar Rock’s
nonclinical and preclinical studies and clinical trials, and
Scholar Rock’s ability to manage expenses and to obtain additional
funding when needed to support its business activities and
establish and maintain strategic business alliances and new
business initiatives, as well as those risks more fully discussed
in the section entitled "Risk Factors" in Scholar Rock’s Annual
Report on Form 10-K for the year ended December 31, 2022, as well
as discussions of potential risks, uncertainties, and other
important factors in Scholar Rock’s subsequent filings with the
Securities and Exchange Commission. Any forward-looking statements
represent Scholar Rock’s views only as of today and should not be
relied upon as representing its views as of any subsequent date.
All information in this press release is as of the date of the
release, and Scholar Rock undertakes no duty to update this
information unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230410005287/en/
Scholar Rock:
Investors Rushmie Nofsinger Scholar Rock
rnofsinger@scholarrock.com ir@scholarrock.com 857-259-5573
Media Teagan White Finn Partners
teagan.white@finnpartners.com media@scholarrock.com
212-583-2729
Scholar Rock (NASDAQ:SRRK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Scholar Rock (NASDAQ:SRRK)
Historical Stock Chart
From Jul 2023 to Jul 2024